Phase II trial of tesmilifene plus mitoxantrone and prednisone for hormone refractory prostate cancer: high subjective and objective response in patients with symptomatic metastases.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples